Working… Menu

A "Negative"Dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial (MS-tolDC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02618902
Recruitment Status : Recruiting
First Posted : December 2, 2015
Last Update Posted : March 12, 2018
Information provided by (Responsible Party):
Nathalie Cools, University Hospital, Antwerp